This decline was primarily driven by a 21.7% YoY drop in net sales to Rs 38.83 crore.
Total operating expenses also decreased by 22.2% to Rs 20.28 crore in the June'24 quarter.
Consequently, PBIDT decreased by 22.4% YoY to Rs 19.07 crore in Q1 FY25, with a margin of 49.11% (down from 49.57% in Q1 FY24).
Further, the company's depreciation charges increased by 53.3% YoY to Rs 1.15 crore during the period under review.
As a result, profit before tax fell by 25% to Rs 17.86 crore in Q1 FY25 compared to Rs 23.81 crore in the corresponding quarter of the previous year.
Gujarat Themis Biosyn is engaged in the manufacturing of APIs, namely, Rifamycin S and Rifamycin O.
The scrip had declined 3.91% to end at Rs 483.75 on the BSE on Friday.
In the last one year, the stock of Gujarat Themis Biosyn has surged 207.26% while the benchmark Sensex had risen 21.92% in the same period.